Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX.
Young Hoon ChoiSang Hyub LeeSang Hyub LeeBang Sup ShinWoo Hyun PaikJi-Kon RyuYong Tae KimWooil KwonJin-Young JangSun Whe KimPublished in: Gut and liver (2021)
In patients with BR or LA pancreatic cancer, FOLFIRINOX is a valuable neoadjuvant treatment that enables curative surgery in approximately one-quarter of patients and significantly improves overall survival. In these patients, the prognosis can be estimated using the lowest level of serum CA 19-9, operative status, and initial FDG-PET SUVmax.
Keyphrases
- locally advanced
- prognostic factors
- rectal cancer
- end stage renal disease
- squamous cell carcinoma
- neoadjuvant chemotherapy
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- radiation therapy
- phase ii study
- computed tomography
- coronary artery disease
- positron emission tomography
- atrial fibrillation
- pet imaging
- smoking cessation
- protein kinase
- percutaneous coronary intervention
- surgical site infection